ARA-290 (35 mg)

Description

ARA-290 (Also known as Cibinetide)

ARA-290 is a synthetic 11-amino acid peptide derived from the helix B domain of erythropoietin (EPO). Unlike full-length EPO, ARA-290 selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis (red blood cell production). It is primarily researched for its potential in neuroprotection, tissue repair, and anti-inflammatory activity.

Research Properties:

• Anti-Inflammatory Effects: ARA-290 has been studied for its ability to reduce pro-inflammatory cytokines such as IL-6, IL-12, and TNF-α, making it of interest in chronic inflammation and autoimmune research models.
• Nerve Repair & Neuroprotection: Shows significant potential in promoting nerve fiber regeneration and functional recovery in models of neuropathic pain and nerve damage.
• Tissue Protection & Wound Healing: Research indicates it may accelerate wound healing and improve tissue survival, particularly in diabetic and ischemic models.
• Immune Modulation: Being investigated for its role in modulating immune responses in various inflammatory conditions.

Key Areas of Research Interest:

• Neuropathic pain and diabetic neuropathy
• Sarcoidosis-associated small fiber neuropathy
• Tissue repair and regeneration
• Inflammatory and autoimmune conditions
• Cardiovascular and retinal protection

Note: ARA-290 has been evaluated in multiple Phase II and Phase III clinical trials for various indications, though it remains a research compound.

For Research Use Only. Not for human consumption. ARA-290 is intended strictly for laboratory research and in-vitro experimentation.